Premium
MATERNAL SERUM ALPHA‐FETOPROTEIN SCREENING IN A PROVINCIAL HEALTH DISTRICT
Author(s) -
Woolfson J.,
Holt E. M.,
Whyman A. E.,
Mabbs D. V.
Publication year - 1979
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1979.tb10573.x
Subject(s) - medicine , amniocentesis , obstetrics , alpha fetoprotein , pregnancy , neural tube , fetus , prenatal diagnosis , gynecology , pediatrics , embryo , genetics , hepatocellular carcinoma , biology , microbiology and biotechnology
Summary Maternal serum alpha‐fetoprotein (AFP) estimation as a routine screening test for neural tube defect (NTD) was introduced into the West Berkshire Health District, where 17 per cent of all deliveries and most of the antenatal care is under‐taken by the general practitioners. In the first year, 4458 patients were screened and 43 of those (0.96 per cent) had raised serum AFP levels. Amniocentesis was performed on 31 patients (0.69 per cent). Ten fetuses with severe NTDs and one with exomphalos were detected and the pregnancies terminated. In six patients, raised serum AFP levels were due to fetal death. No normal pregnancy was terminated. Acceptability by patients was high. Provided that a good diagnostic ultrasound facility is available locally, maternal serum AFP estimation seemed to be a valuable screening test.